Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBITDA Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed EBITDA Margin for 16 consecutive years, with 963.35% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin fell 54296.0% to 963.35% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 585.9% through Sep 2025, up 47640.0% year-over-year, with the annual reading at 562.63% for FY2025, 40644.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 963.35% at IGC Pharma, down from 488.41% in the prior quarter.
  • The five-year high for EBITDA Margin was 360.91% in Q1 2025, with the low at 7721.43% in Q3 2021.
  • Average EBITDA Margin over 5 years is 1871.7%, with a median of 977.29% recorded in 2024.
  • Peak annual rise in EBITDA Margin hit 808621bps in 2021, while the deepest fall reached -650943bps in 2021.
  • Over 5 years, EBITDA Margin stood at 1622.54% in 2021, then surged by 57bps to 695.78% in 2022, then plummeted by -292bps to 2730.88% in 2023, then soared by 74bps to 718.68% in 2024, then plummeted by -34bps to 963.35% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 963.35%, 488.41%, and 360.91% for Q3 2025, Q2 2025, and Q1 2025 respectively.